EVELINE BARBIERI to Humans
This is a "connection" page, showing publications EVELINE BARBIERI has written about Humans.
Connection Strength
0.125
-
Characterization of Persister Cells Provides Insights into Mechanisms of Therapy Resistance in Neuroblastoma. Cancer Discov. 2024 Dec 02; 14(12):2308-2311.
Score: 0.025
-
p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy. Clin Cancer Res. 2017 Nov 01; 23(21):6629-6639.
Score: 0.015
-
Histone chaperone CHAF1A inhibits differentiation and promotes aggressive neuroblastoma. Cancer Res. 2014 Feb 01; 74(3):765-74.
Score: 0.012
-
A p53 drug response signature identifies prognostic genes in high-risk neuroblastoma. PLoS One. 2013; 8(11):e79843.
Score: 0.012
-
MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death. Mol Cancer Ther. 2006 Sep; 5(9):2358-65.
Score: 0.007
-
Treatment and prevention of tumor lysis syndrome in children. Experience of Associazione Italiana Ematologia Oncologia Pediatrica. Contrib Nephrol. 2005; 147:80-92.
Score: 0.006
-
Reactivation of the G1 enhancer landscape underlies core circuitry addiction to SWI/SNF. Nucleic Acids Res. 2024 Jan 11; 52(1):4-21.
Score: 0.006
-
CHAF1A Blocks Neuronal Differentiation and Promotes Neuroblastoma Oncogenesis via Metabolic Reprogramming. Adv Sci (Weinh). 2021 10; 8(19):e2005047.
Score: 0.005
-
Restoration of the molecular clock is tumor suppressive in neuroblastoma. Nat Commun. 2021 06 28; 12(1):4006.
Score: 0.005
-
The Anti-Tumor Activity of the NEDD8 Inhibitor Pevonedistat in Neuroblastoma. Int J Mol Sci. 2021 Jun 18; 22(12).
Score: 0.005
-
The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53. Neoplasia. 2021 06; 23(6):624-633.
Score: 0.005
-
Circulating microRNA biomarkers for metastatic disease in neuroblastoma patients. JCI Insight. 2018 12 06; 3(23).
Score: 0.004
-
NSC-87877 inhibits DUSP26 function in neuroblastoma resulting in p53-mediated apoptosis. Cell Death Dis. 2015 Aug 06; 6:e1841.
Score: 0.003
-
G-CSF receptor positive neuroblastoma subpopulations are enriched in chemotherapy-resistant or relapsed tumors and are highly tumorigenic. Cancer Res. 2013 Jul 01; 73(13):4134-46.
Score: 0.003
-
A genome-wide search for promoters that respond to increased MYCN reveals both new oncogenic and tumor suppressor microRNAs associated with aggressive neuroblastoma. Cancer Res. 2011 Jun 01; 71(11):3841-51.
Score: 0.002
-
Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma. Angiogenesis. 2011 Sep; 14(3):255-66.
Score: 0.002
-
Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo. Neoplasia. 2009 Aug; 11(8):753-62.
Score: 0.002
-
Efficacy and safety of recombinant urate oxidase (rasburicase) for treatment and prophylaxis of hyperuricemia in children undergoing chemotherapy. Haematologica. 2005 Jan; 90(1):141-2.
Score: 0.002
-
Gonadal function and pubertal development after treatment of a childhood malignancy. J Pediatr Endocrinol Metab. 2003 Mar; 16 Suppl 2:321-6.
Score: 0.001
-
Low birth weight for gestational age and subsequent male gonadal function. J Pediatr. 2002 Sep; 141(3):376-9.
Score: 0.001
-
Inhibin B levels in adolescents and young adults with type 1 diabetes. Horm Res. 2002; 57(5-6):205-8.
Score: 0.001
-
Final height of short subjects of low birth weight with and without growth hormone treatment. Arch Dis Child. 2001 Apr; 84(4):340-3.
Score: 0.001